PGIM India Healthcare Fund Regular Growth

Fund Overview

Fund Size

₹108 Cr

Expense Ratio

2.38%

ISIN

INF663L01Z52

Minimum SIP

₹1,000

Exit Load

No Charges

Inception Date

06 Dec 2024

About this fund

This fund has been in existence for 5 months and 7 days, having been launched on 06-Dec-24.
As of 12-May-25, it has a Net Asset Value (NAV) of ₹9.45, Assets Under Management (AUM) of 107.51 Crores, and an expense ratio of 2.38%.

PGIM India Healthcare Fund Regular Growth has given a CAGR return of -5.50% since inception.
The fund's asset allocation comprises around 95.07% in equities, 0.00% in debts, and 4.93% in cash & cash equivalents.
You can start investing in PGIM India Healthcare Fund Regular Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

Since Inception

-5.50%

— (Cat Avg.)

Portfolio Summaryas of 30th April 2025

Equity	₹102.2 Cr	95.07%
Others	₹5.31 Cr	4.93%

Top Holdings

All Holdings

Equity

Debt & Others

Name	Type	Amount	Holdings
Sun Pharmaceuticals Industries Ltd	Equity	₹14.04 Cr	13.06%
Divi's Laboratories Ltd	Equity	₹8.34 Cr	7.75%
Max Healthcare Institute Ltd Ordinary Shares	Equity	₹7.46 Cr	6.94%
Dr Reddy's Laboratories Ltd	Equity	₹6.5 Cr	6.04%
Mankind Pharma Ltd	Equity	₹5.2 Cr	4.83%
Aster DM Healthcare Ltd Ordinary Shares	Equity	₹5.14 Cr	4.78%
Clearing Corporation Of India Ltd.	Cash - Repurchase Agreement	₹4.88 Cr	4.54%
Torrent Pharmaceuticals Ltd	Equity	₹4.19 Cr	3.90%
Krishna Institute of Medical Sciences Ltd	Equity	₹3.85 Cr	3.58%
Ajanta Pharma Ltd	Equity	₹3.58 Cr	3.33%
Abbott India Ltd	Equity	₹3.56 Cr	3.31%
J.B. Chemicals & Pharmaceuticals Ltd	Equity	₹3.39 Cr	3.15%
Global Health Ltd	Equity	₹3.17 Cr	2.95%
ICICI Lombard General Insurance Co Ltd	Equity	₹3.08 Cr	2.86%
Cipla Ltd	Equity	₹3.05 Cr	2.84%
PB Fintech Ltd	Equity	₹2.81 Cr	2.61%
Dr. Lal PathLabs Ltd	Equity	₹2.62 Cr	2.43%
Jupiter Life Line Hospitals Ltd	Equity	₹2.44 Cr	2.27%
Navin Fluorine International Ltd	Equity	₹2.35 Cr	2.18%
Ipca Laboratories Ltd	Equity	₹2.25 Cr	2.10%
Syngene International Ltd	Equity	₹2.22 Cr	2.06%
Rainbow Childrens Medicare Ltd	Equity	₹2.08 Cr	1.93%
Sagility India Ltd	Equity	₹2.05 Cr	1.91%
Neuland Laboratories Ltd	Equity	₹2.03 Cr	1.89%
Sanofi Consumer Healthcare India Ltd	Equity	₹1.94 Cr	1.81%
Sanofi India Ltd	Equity	₹1.72 Cr	1.60%
Zydus Lifesciences Ltd	Equity	₹1.05 Cr	0.97%
Sai Life Sciences Ltd	Equity	₹1.02 Cr	0.94%
Orchid Pharma Ltd	Equity	₹0.77 Cr	0.72%
Net Receivables / (Payables)	Cash	₹0.42 Cr	0.39%
Akums Drugs and Pharmaceuticals Ltd	Equity	₹0.32 Cr	0.29%

Allocation By Market Cap (Equity)

Other Allocation

Equity Sector

Debt & Others

Sector	Amount	Holdings
Healthcare	₹93.97 Cr	87.41%
Financial Services	₹5.88 Cr	5.47%
Basic Materials	₹2.35 Cr	2.18%

Risk & Performance Ratios

Fund Managers

Puneet Pal

Since January 2025

Anandha Padmanabhan Anjeneyan

Since January 2025

Utsav Mehta

Since January 2025

Vivek Sharma

Since January 2025

Additional Scheme Detailsas of 30th April 2025

ISIN

INF663L01Z52

Expense Ratio

2.38%

Exit Load

No Charges

Fund Size

₹108 Cr

Age

5 months

Lumpsum Minimum

₹5,000

Fund Status

Open Ended Investment Company

Benchmark

BSE Healthcare TR INR

Investment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Capital Gains Taxation:

Dividend Taxation:

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹310.41 Cr	-
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk	0.7%	1.0%	₹310.41 Cr	-
PGIM India Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹107.51 Cr	-
PGIM India Healthcare Fund Regular Growth Very High Risk	2.4%	0.0%	₹107.51 Cr	-
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹303.62 Cr	26.5%
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk	0.7%	1.0%	₹303.62 Cr	28.8%
DSP Nifty Healthcare ETF Regular Growth Very High Risk	0.2%	-	₹10.03 Cr	17.6%
Kotak Healthcare Fund Direct Growth Very High Risk	0.8%	0.0%	₹411.54 Cr	17.0%
Kotak Healthcare Fund Regular Growth Very High Risk	2.4%	0.0%	₹411.54 Cr	15.1%
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk	2.0%	1.0%	₹1634.08 Cr	27.0%
HDFC Pharma and Healthcare Fund Direct Growth Very High Risk	0.9%	1.0%	₹1634.08 Cr	28.5%
Nippon India Pharma Fund Direct Growth Very High Risk	0.9%	1.0%	₹8259.60 Cr	15.6%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Regular Growth Very High Risk	1.9%	1.0%	₹4914.64 Cr	22.8%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth Very High Risk	1.2%	1.0%	₹4914.64 Cr	23.8%
DSP Healthcare Fund Direct Growth Very High Risk	0.6%	0.0%	₹2912.01 Cr	13.4%
DSP Healthcare Fund Regular Growth Very High Risk	1.9%	0.0%	₹2912.01 Cr	11.9%
LIC MF Healthcare Fund Direct Growth Very High Risk	1.2%	1.0%	₹84.18 Cr	18.1%
LIC MF Healthcare Fund Regular Growth Very High Risk	2.5%	1.0%	₹84.18 Cr	16.6%
quant Healthcare Fund Direct Growth Very High Risk	0.8%	1.0%	₹395.99 Cr	13.9%
quant Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹395.99 Cr	12.0%
UTI Healthcare Fund Direct Growth Very High Risk	1.2%	1.0%	₹1037.49 Cr	21.8%
SBI Healthcare Opportunities Fund Direct Growth Very High Risk	0.9%	0.0%	₹3670.62 Cr	22.8%
Tata India Pharma & Healthcare Fund Regular Growth Very High Risk	2.1%	0.0%	₹1222.72 Cr	16.7%
Tata India Pharma & Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹1222.72 Cr	18.5%
ICICI Prudential Nifty Healthcare ETF Very High Risk	0.1%	-	₹130.69 Cr	17.6%
SBI Healthcare Opportunities Fund Regular Growth Very High Risk	1.9%	0.0%	₹3670.62 Cr	21.5%
Nippon India Pharma Fund Regular Growth Very High Risk	1.8%	1.0%	₹8259.60 Cr	14.6%
UTI Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹1037.49 Cr	20.6%
Axis NIFTY Healthcare ETF Very High Risk	0.3%	-	₹19.30 Cr	17.4%
Nippon India Nifty Pharma ETF Very High Risk	0.2%	-	₹887.84 Cr	13.8%
Mirae Asset Healthcare Fund Regular Growth Very High Risk	2.0%	1.0%	₹2667.40 Cr	17.6%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹2667.40 Cr	19.3%
ITI Pharma and Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹213.77 Cr	17.0%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹213.77 Cr	19.2%
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk	0.2%	-	₹36.33 Cr	17.5%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹818.33 Cr	12.1%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk	1.1%	1.0%	₹818.33 Cr	13.6%
Motilal Oswal S&P BSE Healthcare ETF Very High Risk	0.2%	-	₹29.04 Cr	20.2%

Risk Level

Your principal amount will be at Very High Risk

Take control of your wealth

Track and Analyse all your investments with Wealth Monitor

Rated ★ 4.3+ on

Still got questions?
We're here to help.

What is the current NAV of PGIM India Healthcare Fund Regular Growth?

The NAV of PGIM India Healthcare Fund Regular Growth, as of 12-May-2025, is ₹9.45.

What is the portfolio composition of PGIM India Healthcare Fund Regular Growth?

The fund's allocation of assets is distributed as 95.07% in equities, 0.00% in bonds, and 4.93% in cash and cash equivalents.

Who manages the PGIM India Healthcare Fund Regular Growth?

The fund managers responsible for PGIM India Healthcare Fund Regular Growth are:-

Puneet Pal
Anandha Padmanabhan Anjeneyan
Utsav Mehta
Vivek Sharma

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.

;

Fund Overview

Fund Size

₹108 Cr

Expense Ratio

2.38%

ISIN

INF663L01Z52

Minimum SIP

₹1,000

Exit Load

No Charges

Inception Date

06 Dec 2024

Risk Level

Your principal amount will be at Very High Risk